相似文献
1
A leave-one-out cross-validation SAS macro for the identification of markers associated with survival.
Comput Biol Med. 2015 Feb;57:123-9. doi: 10.1016/j.compbiomed.2014.11.015. Epub 2014 Dec 9.
2
A SAS macro for a clustered permutation test.
Comput Methods Programs Biomed. 2009 Jul;95(1):89-94. doi: 10.1016/j.cmpb.2009.02.005. Epub 2009 Mar 24.
3
Predictive survival model with time-dependent prognostic factors: development of computer-aided SAS Macro program.
J Eval Clin Pract. 2005 Apr;11(2):181-93. doi: 10.1111/j.1365-2753.2005.00519.x.
4
A SAS macro for sample size re-estimation.
Comput Methods Programs Biomed. 2001 Jun;65(3):183-90. doi: 10.1016/s0169-2607(00)00119-x.
5
Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis.
Lancet Oncol. 2018 Jul;19(7):930-939. doi: 10.1016/S1470-2045(18)30294-8. Epub 2018 Jun 13.
6
A SAS macro for a clustered logrank test.
Comput Methods Programs Biomed. 2011 Nov;104(2):266-70. doi: 10.1016/j.cmpb.2011.02.001. Epub 2011 Apr 15.
7
Feature selection and nearest centroid classification for protein mass spectrometry.
BMC Bioinformatics. 2005 Mar 23;6:68. doi: 10.1186/1471-2105-6-68.
8
A SAS macro for parametric and semiparametric mixture cure models.
Comput Methods Programs Biomed. 2007 Feb;85(2):173-80. doi: 10.1016/j.cmpb.2006.10.008. Epub 2006 Dec 8.
9
%svy_logistic_regression: A generic SAS macro for simple and multiple logistic regression and creating quality publication-ready tables using survey or non-survey data.
PLoS One. 2019 Sep 3;14(9):e0214262. doi: 10.1371/journal.pone.0214262. eCollection 2019.
10
Does the SORG Algorithm Predict 5-year Survival in Patients with Chondrosarcoma? An External Validation.
Clin Orthop Relat Res. 2019 Oct;477(10):2296-2303. doi: 10.1097/CORR.0000000000000748.
引用本文的文献
1
The effect of durvalumab consolidation after definitive radiochemotherapy for non-operable stage III non-small cell lung cancer on the dose effect relation for therapy related pulmonary infiltrates as a risk factor for pneumonitis.
Transl Lung Cancer Res. 2025 Jun 30;14(6):2074-2088. doi: 10.21037/tlcr-2024-1284. Epub 2025 Jun 26.
2
Predicting no-shows at outpatient appointments in internal medicine using machine learning models.
PeerJ Comput Sci. 2025 Apr 22;11:e2762. doi: 10.7717/peerj-cs.2762. eCollection 2025.
3
A Mendelian randomization study of genetic liability to cutaneous melanoma and sunburns.
Front Oncol. 2024 Aug 30;14:1393833. doi: 10.3389/fonc.2024.1393833. eCollection 2024.
4
C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiochemotherapy.
Sci Rep. 2024 Jun 14;14(1):13765. doi: 10.1038/s41598-024-64302-2.
5
Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment-Comparison with Stage III Disease.
Cancers (Basel). 2024 Mar 17;16(6):1174. doi: 10.3390/cancers16061174.
6
Identification of early risk factors for anti-citrullinated-protein-antibody positive rheumatoid arthritis-a prospective cohort study.
Rheumatology (Oxford). 2024 Nov 1;63(11):3164-3171. doi: 10.1093/rheumatology/keae146.
7
Wearable Sensors as a Preoperative Assessment Tool: A Review.
Sensors (Basel). 2024 Jan 12;24(2):482. doi: 10.3390/s24020482.
8
Genetically predicted the causal relationship between gut microbiota and infertility: bidirectional Mendelian randomization analysis in the framework of predictive, preventive, and personalized medicine.
EPMA J. 2023 Jul 7;14(3):405-416. doi: 10.1007/s13167-023-00332-6. eCollection 2023 Sep.
9
Prognostic Value of CD8+ Lymphocytes in Hepatocellular Carcinoma and Perineoplastic Parenchyma Assessed by Interface Density Profiles in Liver Resection Samples.
Cancers (Basel). 2023 Jan 5;15(2):366. doi: 10.3390/cancers15020366.
10
Should We Always Perform Preoperative Chest Computed Tomography in Patients with cT1a Renal Cell Carcinoma?
Cancers (Basel). 2022 Nov 12;14(22):5558. doi: 10.3390/cancers14225558.
本文引用的文献
1
Integrative Pathway Analysis Using Graph-Based Learning with Applications to TCGA Colon and Ovarian Data.
Cancer Inform. 2014 Jul 28;13(Suppl 4):1-9. doi: 10.4137/CIN.S13634. eCollection 2014.
2
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).
Clin Cancer Res. 2013 Dec 15;19(24):6957-66. doi: 10.1158/1078-0432.CCR-13-0926. Epub 2013 Oct 4.
3
Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab.
Cancer Med. 2013 Apr;2(2):234-42. doi: 10.1002/cam4.71. Epub 2013 Mar 6.
4
Development of a prognostic model for breast cancer survival in an open challenge environment.
Sci Transl Med. 2013 Apr 17;5(181):181ra50. doi: 10.1126/scitranslmed.3005974.
5
Sample size considerations of prediction-validation methods in high-dimensional data for survival outcomes.
Genet Epidemiol. 2013 Apr;37(3):276-82. doi: 10.1002/gepi.21721. Epub 2013 Mar 7.
6
A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.
Blood. 2012 Aug 9;120(6):1197-201. doi: 10.1182/blood-2012-01-403279. Epub 2012 Jun 26.
7
Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.
BMC Med. 2012 May 29;10:51. doi: 10.1186/1741-7015-10-51.
8
A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer.
Oncologist. 2011;16(8):1131-7. doi: 10.1634/theoncologist.2011-0078. Epub 2011 Jul 27.
9
Integrated genomic analyses of ovarian carcinoma.
Nature. 2011 Jun 29;474(7353):609-15. doi: 10.1038/nature10166.
10
On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data.
Stat Med. 2011 May 10;30(10):1105-17. doi: 10.1002/sim.4154. Epub 2011 Jan 13.
Zotero 插件